Spike Protein News and Research

RSS

Single mRNA vaccine dose may be enough for those previously exposed to SARS-CoV-2

New research supports the notion that those who have recovered from COVID-19, caused by SARS-CoV-2 infection, may only need one dose of an mRNA vaccine to boost immunity.

10 Mar 2021

Neutralizing antibodies may be evolving to keep up with SARS-CoV-2 mutations

Viruses evolve under increased pressure, and new research from The Rockefeller University and University of Massachusetts Medical School in the U.S. suggests our antibodies can as well.

10 Mar 2021

New SARS-CoV-2 vaccine candidate produces strong immune response, prevents SARS-CoV-2 infection

A new SARS-CoV-2 vaccine candidate, developed by giving a key protein's gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies.

10 Mar 2021

Researchers discover new COVID-19 variants in three South African provinces

Variants of the coronavirus are appearing in different parts of the world, many of them spreading with alarming speed.

10 Mar 2021

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

In a recent bioRxiv* preprint paper, researchers isolated anti-RBD nanobodies from llamas and “nanomice” (they engineered to produce VHHs cloned from alpacas, dromedaries and camels).

10 Mar 2021

SARS-CoV-2 variants rapidly arise in non-human hosts, potential risk for human reinfection

The study, published on the preprint server bioRxiv*, highlights the need to study viral evolution and pathogenesis in human and animal hosts. This could help prevent future outbreaks that may mimic the magnitude of the current COVID-19 pandemic.

9 Mar 2021

A genetic variant of TMPRSS2 may confer protection against severe COVID-19

Among a large sample of COVID-19 patients, researchers found that a genetic variant – caused by an amino acid substitution from valine to methionine – is associated with a reduced chance of severe disease.

9 Mar 2021

Researchers report zoonotic spillover of adapted SARS-CoV-2 from minks to humans

In a recent report made available on bioRxiv* preprint server, researchers from Poland and Finland reveal a spillover event of mink-adapted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from farmed mink to humans after an extensive adaptation process.

9 Mar 2021

Greater cross-neutralization against UK SARS-CoV-2 variant in vaccinated individuals with prior infection

A team of researchers in Spain has observed that, of those who have been vaccinated against SARS-CoV-2, higher titers of neutralizing antibodies for the B.1.1.7 variant (originating in the UK) were present in those who had previously been infected with the virus.

9 Mar 2021

Ultraviolet light therapy reduces viral load in critically ill COVID-19 patients

Scientists from the United States has recently evaluated the safety and efficacy profiles of ultraviolet-A (UVA) light applied via an endotracheal tube to critically ill COVID-19 patients.

9 Mar 2021

Study suggests sewer rats immune to SARS-CoV-2

Although the researchers found that the rats tested negative for the virus, they say it is important to continue monitoring animals for the virus as it mutates, making previously resistant species susceptible to infection.

8 Mar 2021

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers at the Pitié Salpêtrière Hospital, Department of Virology, Paris, France determined that in BNT162b2-vaccinated participants who received two doses, their sera harbored at least a neutralizing titer against the three SARS-CoV-2 variants.

8 Mar 2021

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

A new study of the U.K. and South Africa variants of SARS-CoV-2 predicts that current vaccines and certain monoclonal antibodies may be less effective at neutralizing these variants and that the new variants raise the specter that reinfections could be more likely.

8 Mar 2021

Worse problems with SARS-CoV-2 variants may be on the way

Researchers at the Department of Integrative Biomedical Sciences, University of Cape Town, South Africa, found evidence of a significant change in the selective forces acting on immunologically important SARS-CoV-2 genes, such as N and S. These likely coincided with the emergence of the 501Y lineages.

8 Mar 2021

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

A team of scientists from Israel has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine, BNT162b2, in inducing host humoral immune response. The findings reveal that the vaccine is capable of inducing strong anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and that the response varies significantly with age. The study is currently available on the medRxiv* preprint server.

8 Mar 2021

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.

8 Mar 2021

Researchers present fragment-based computational design of antibodies that target structured epitopes

A new study describes a novel fragment-based method to design antibody complementarity determining region (CDR) loops.

8 Mar 2021

Apoptosis is an important mediator of pathogenesis in animal coronavirus infection

A new paper in the journal Life presents an early review of the viral factors involved in initiating and effecting apoptosis within infected cells.

8 Mar 2021

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

A monoclonal antibody "cocktail" developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.

5 Mar 2021

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

A new study details the results from a single dose of the FINLAY FR 1A recombinant dimeric receptor-binding domain (RBD) base vaccine during a phase I clinical trial with 30 COVID-19 convalescents to test its capacity for boosting natural immunity.

5 Mar 2021

Spike Protein News and Research

Single mRNA vaccine dose may be enough for those previously exposed to SARS-CoV-2

Neutralizing antibodies may be evolving to keep up with SARS-CoV-2 mutations

New SARS-CoV-2 vaccine candidate produces strong immune response, prevents SARS-CoV-2 infection

Researchers discover new COVID-19 variants in three South African provinces

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

SARS-CoV-2 variants rapidly arise in non-human hosts, potential risk for human reinfection

A genetic variant of TMPRSS2 may confer protection against severe COVID-19

Researchers report zoonotic spillover of adapted SARS-CoV-2 from minks to humans

Greater cross-neutralization against UK SARS-CoV-2 variant in vaccinated individuals with prior infection

Ultraviolet light therapy reduces viral load in critically ill COVID-19 patients

Study suggests sewer rats immune to SARS-CoV-2

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

Worse problems with SARS-CoV-2 variants may be on the way

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers present fragment-based computational design of antibodies that target structured epitopes

Apoptosis is an important mediator of pathogenesis in animal coronavirus infection

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

Pioneering Live Cell Imaging - Yokogawa's Impact and Innovations

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Latest News